Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6621 in Metastatic Prostate Cancer
NCT07192614Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of AZD6621 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE) up to 3 years, Number of participants with dose-limiting toxicity and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
AZD6621
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07192614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192614.